This is at flowchart to illustrate the different phases of retrospective and prospective study plans, and where our projects are in the process in terms of TK 210 ELISA studies in various types of cancers, for example breast, prostate, lung, colon, and sarcoma cancers
Ongoing retrospective studies:
Hematological cancers, U-CAN
Study of 190 patients, with patient sampling prior to treatment, during treatment and at follow-up or relapse. Endpoints: prognosis for disease free survival, predictive value (treatment efficiency), and early detection of relapse.
Breast cancer, Promix, Karolinska Stockholm
Neoadjuvant chemotherapy study of the contribution of TK 210 ELISA to monitoring treatment efficiency (predictive value), and survival in relation to TK 210 levels (prognosis).
Ongoing prospective studies:
Sarcoma study, Helsinki
Objective: to evaluate if TK 210 ELISA has the potential to function as a prognostic indicator and as an early marker of cancer recurrence.
Serum is sampled at diagnosis, after primary therapy and, in patients with successful anti-cancer therapy, at one-year follow-up. Serum will also be sampled in cases of sarcoma recurrence or detection of metastasis.
At data analysis, the levels of Thymidine Kinase 1, measured by TK 210 ELISA, will be related to disease progression and to e.g. tumor size and histologic sarcoma grade.
Prostate cancer, Stockholm South General Hospital
Objective: to validate the prognostic and monitoring capacity of TK 210 ELISA in males with suspected and/or confirmed prostate cancer. Patients will be divided into different risk groups per the D’Amico risk group classification in which both total and free PSA and the more extensive Gleeson score is taken into consideration. TK 210 ELISA will be measured at the first visit and then 2-4 times per year during follow up. It will be evaluated if the risk group assessment benefit from including TK 210 ELISA to make a more accurate prognosis.
Ongoing clinical collaboration:
AroCell AB has a longstanding research and clinical collaboration with the University Medical Centre, Ljubljana, Slovenia. Two currently ongoing projects are described below:
Prostate cancer, Ljubljana
Objective: To validate the predictive value of TK 210 ELISA serum samples from men diagnosed with prostate cancer at the University Medical Centre Ljubljana. Serum will be collected before and after treatment and analyzed with respect to TK 210 ELISA. The TK 210 levels will also be evaluated in relation to free and total PSA, PSA pro and Prostate Health Index, a scoring index that takes many parameters into consideration.
Breast cancer, Ljubljana
Objective: To validate the predictive value of TK 210 ELISA serum samples from women diagnosed with breast cancer at the University Medical Centre Ljubljana will be collected before and after treatment and analyzed with TK 210 ELISA. The stage of the cancer and levels of the breast cancer biomarker CA 15-3 will also be evaluated in relation to TK 210 ELISA levels.